공시 • Sep 09
ChitogenX Inc. announced that it expects to receive CAD 0.3 million in funding ChitogenX Inc. announced that it has entered into a binding letter of intent for a private placement of secured debentures for a gross proceeds of $300,000 on September 8, 2025. The transaction will include participation from new lender, Oligo Medic. 공시 • Nov 10
Chitogenx Inc. Demonstrates ORTHO-R Efficacy and Osteoarthritidevelopment in Large Animal Study ChitogenX Inc. announced that ORTHO-R, its proprietary chitosan/PRP based biopolymer matrix, has successfully demonstrated protection from joint degeneration post meniscal repair surgery in a large animal study. In a study of 22 mature sheep, a radial meniscus tear was surgically induced and immediately surgically repaired. The sheep were randomized to three groups: surgery alone,ii) surgery and PRP, and surgery + ORTHO-R and PRP combined. Results were observed 6 months post-surgery. Results showed that the large majority of menisci from the two control groups (surgery alone or surgery + PRP alone) experienced severe structural changes and most control sheep displayed moderate to severe signs of osteoarthritis ("OA"). The medial menisci from the ORTHO-R treated group retained better structure and much milder form of OA and, in some cases, appeared near normal. This study provides the first evidence that treatment with ChitogenX's proprietary chitosan-based biopolymer + PRP prevents structural changes to radially incised and sutured menisci in a large animal model, and most likely contributed to protecting the joints against OA development. This study contributes to a growing and strong body of evidence that the Company's proprietary chitosan -based biopolymer, combined with PRP can potentially bring significant benefit to human tissue repair. 공시 • Sep 27
Chitogenx Concludes Enrolment for Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial ChitogenX Inc. announced that it has concluded enrolment at 20 subjects in its U.S. multi-site rotator cuff tear repair phase I/II clinical trial entitled: A Blinded, Randomized Controlled Study Investigating the Safety of Ortho-R® for Rotator Cuff Repair Compared with Standard of Care: ORT-2020-01 (Ortho-R® Study). All study activities will be completed by June 2024 as per the clinical trial protocol following completion of the clinical follow-up and safety analysis for the 20 recruited subjects. Study results are expected during the summer of 2024. ChitogenX is grateful to the sites and subjects for their contribution to this important clinical trial. Thus far, there have been no safety issues reported with every subject having been treated between 3 and 12 months. The original U.S. Phase I/II clinical trial protocol was for a blinded, randomized controlled study investigating the safety of ORTHO-R® for rotator cuff tear repair compared with standard of care in a total of 78 subjects at ten clinical sites throughout the U.S. The return on the investment required to complete the full recruitment of the trial is difficult to justify based on the little incremental benefit expected statistically. 공시 • May 27
ChitogenX Inc., Annual General Meeting, Jul 19, 2023 ChitogenX Inc., Annual General Meeting, Jul 19, 2023. 공시 • May 06
ChitogenX Inc. announced that it has received CAD 3.856348 million in funding On May 5, 2023, ChitogenX Inc. closed the transaction. The company has issued 25,708,988 units at a price of CAD 0.15 per unit for total gross proceeds of CAD 3,856,348.20. The transaction included participation from Insiders for CAD 1,800,000. 공시 • Feb 15
ChitogenX Inc. Demonstrates Ortho-R Residency Properties in Meniscus Study ChitogenX Inc. announced that it has successfully confirmed soft-tissue residency properties of its chitosan/PRP based biopolymer matrix, ORTHO-R, in a grant-supported large animal meniscus tear repair study. The meniscus tear repair study confirmed the presence of tissue adherence and the aggregation of PRP regenerative cells imbedded in the tear. It represents the second orthopedic ORTHO-R soft tissue proof of concept application to be successfully confirmed following similar results generated in a previously reported similar study for rotator cuff tear repair. 공시 • Feb 10
ChitogenX Inc. announced that it expects to receive CAD 6.1 million in funding ChitogenX Inc. announced a best-efforts private placement of 19,333,333 units at an issue price of CAD 0.225 per unit for gross proceeds of up to CAD 4,349,999.925, and non-brokered private placement issue up to 7,777,777 units at an issue price of CAD 0.225 per unit for gross proceeds of up to CAD 1,749,999.825 on February 9, 2023. Each unit will consist of one class A share of the company and one share purchase warrant of the company. Each warrant will entitle the holder to purchase one share of the company at a price of CAD 0.35 per warrant share at any time on or before the date which is 60 months after the closing date of the offering, subject to adjustment in certain events. If, at any time following the date that is 6 months following the closing date, the daily volume weighted average trading price of the shares on the Canadian Securities Exchange is greater than CAD 0.50 per share for the preceding 10 consecutive trading days, the company shall have the right to accelerate the expiry date of the warrants to a date that is at least 30 days following the date of such notice to holders of warrants. The company has granted the agents an option to arrange for the sale of up to an additional 15% of the units at the issue price. The agent’s option may be exercised in whole or in part at any time up to 48 hours prior to the closing date, subject to limitations prescribed by the LIFE exemption. The best-efforts private placement and non-brokered private placement is scheduled to close on or around February 28, 2023, and is subject to certain conditions including, but not limited to, receipt of all necessary approvals including satisfaction of listing conditions of the Canadian Securities Exchange. The closing of the best-efforts private placement is conditional upon the closing of the non-brokered private placement. 